Please assess the completion status of the following clinical trial:

Trial Title: Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have a histologically-confirmed diagnosis of follicular non-Hodgkin's B-cell lymphoma, grade 1-2 (grade 1 or grade 2 by WHO classification prior to 2009).~2. Patients must have Ann Arbor Stage III or IV extent of disease after complete staging.~3. Patients must have a willingness and ability to follow prescribed radiation precautions~4. Patients must not have had any previous treatment for low-grade lymphoma including chemotherapy or radiation. They may be newly diagnosed or observed without treatment after diagnosis. Symptomatic and asymptomatic patients will be eligible.~5. Patients must have a performance status of 0-2 on the Eastern Cancer Oncology Group (ECOG) scale and an anticipated survival of at least 3 months.~6. Patients must have an absolute neutrophil count \>1500 cells/mm3 and a platelet count \>100,000 cells/mm3 within 14 days of study entry. These blood counts must be sustained without support of hematopoietic cytokines or transfusion of blood products.~7. Patients must have adequate renal function (defined as serum creatinine \<2.0) and hepatic function (defined as total bilirubin \<1.5 x ULN and Aspartate Aminotransferase (AST) \<3 x ULN) within 14 days of study entry.~8. Patients must have bi-dimensionally measurable disease.~Exclusion Criteria:~1. Patients with follicular Grade 3a or 3b by WHO Classification.~2. Patients with evidence of active infection requiring IV antibiotics at the time of study entry.~3. Patients with New York Heart Association Class III or IV heart disease or other serious illness that would preclude evaluation.~4. Patients with active obstructive hydronephrosis.~5. Patients with prior malignancy other than lymphoma, except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years.~6. Patients with known HIV infection.~7. Patients with known brain or leptomeningeal metastases.~8. Patients who are pregnant or nursing. Patients of childbearing potential must undergo a pregnancy test within 7 days of study entry and methotrexate is not to be administered until a negative result is obtained. Males and females must agree to use effective contraception for 6 months following the radioimmunotherapy.~9. Patients with previous allergic reactions to iodine. This does not include reacting to IV iodine-containing contrast materials.~10. Patients with previous allergic reactions to methotrexate.~11. Patients who were previously given any monoclonal antibody, regardless of species, for any condition.~12. Detectable serum levels of HAMA.~13. Patients who are concurrently receiving either approved or non-approved (through another protocol) anti-cancer drugs or biologics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): Low dose methotrexate and Bexxar

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility